Trial Profile
A Multicenter, Parallel-Group, Controlled, Randomized, Double-Blind Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Dec 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 12 Dec 2017 Results (n=331) of subgroup analysis (African American and White) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2015 Results of matched comparison between RevLite and other two phase III trials ( MM009 and MM010) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 08 Jun 2009 A subset analyses of pooled data from this trial and study MM010 has been published in the European Journal of Hematology, according to a Celgene media release.